Introduction: The silent killer disease-Ovarian carcinoma ranks 6th among carcinomas in women. Surface epithelial tumours constitute 90-95% of them. Vascular Endothelial Growth Factor is a Tumour angiogenesis factor. Bevacizumab-anti VEGF antibody shows promise in the treatment of ovarian cancer. Compared to benign ovarian lesions,early stage ovarian cancer patients showed raised levels of VEGF. When used in combination with CA 125, sensitivity increased upto 96%, specificity increased upto 77%. Aims: To study the expression of VEGF (Vascular Endothelial Growth Factor) in epithelial ovarian neoplasms which could thence be, used as therapeutic targets in future. Methods and Material: In the 3 year study from June 2012 to june 2015, out of 92 surface epithelial ovarian neoplasms received, 26 ovarian malignancies and 4 borderline tumors were randomly selected for VEGF immunohistochemistry and statistical analysis was done. Results: Maximum number of patients presented only at an advanced stage of ovarian carcinoma. Among malignancies, 84.02% showed VEGF positivity. Carcinomas showed higher degree of VEGF positivity compared to borderline tumors. Higher the stage and grade, greater was the expression of VEGF and these were found to be statistically significant. Conclusions: VEGF has both diagnostic and therapeutic implications. There is a wide arena of community based studies and research activities being carried out with this marker - opening up newer dimensions and horizons in the early diagnosis and chemotherapeutic approaches with anti VEGF antibodies in the battle against this silent killer called Cancer Ovary.

Keywords: Vascular Endothelial Growth Factor; Tyrosine Kinase; Tumor Angiogenesis.